Description & Learning Objectives
This content was originally presented during the 2023 ASNR Annual Meeting, held in Chicago, April 29-May 3, 2023.
Upon completion of this activity, participants will gain strategies to:
-Discuss neuroimaging adding value in clinical care by improving health outcomes and healthcare delivery.
-Evaluate imaging and determine patient management and treatment.
-Describe ways to improve quality and safety in neuroimaging.
-Review methods to improve patient outcomes utilizing advanced neuroimaging.
Upon completion of this activity, participants will gain strategies to:
-Discuss neuroimaging adding value in clinical care by improving health outcomes and healthcare delivery.
-Evaluate imaging and determine patient management and treatment.
-Describe ways to improve quality and safety in neuroimaging.
-Review methods to improve patient outcomes utilizing advanced neuroimaging.
Instructions for Participation
To complete this activity, learners will watch recordings of conference sessions and submit a course evaluation. Once all elements are completed, a certificate will be automatically added to your transcript.
Credit Dates
Available: 1/1/2024
Expires: 12/31/2026
Expires: 12/31/2026
Accreditation Statement
The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Neuroradiology designates this enduring material for a maximum of 68 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Neuroradiology designates this enduring material for a maximum of 68 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure
In compliance with ACCME requirements and guidelines, ASNR has developed a policy for disclosure and review of potential conflicts of interest and a method for resolution if a conflict does exist. ASNR maintains a tradition of scientific integrity and objectivity in its educational activities. In order to preserve these values and ensure its educational activities are independent and free of commercial bias, all individuals, including planners, presenters, moderators and evaluators, participating in an ASNR educational activity, or an activity jointly provided by ASNR must disclose all relevant financial relationships with ineligible companies, as defined by the ACCME. Unless listed below, all planners and individuals in control of content have nothing to disclose.
- Aboian, Mariam: Blue Earth Diagnostics, Other Financial or Material Support; Fusion Diagnostics, Other Financial or Material Support
- Amans, Matthew: VS3 Medical, Stock Shareholder, Scientific/Medical Advisory Board Member, Consultant, Founder; Stryker, Consultant; Microvention, Scientific/Medical Advisory Board Member; Medtronic, Consultant
- Avey, Gregory: GE Healthcare, Consultant, Paid to institution
- Benzinger, Tammie: Biogen, Consultant, Financial payments to me, Current/Ongoing; Eisai, Scientific/Medical Advisory Board Member, Consultant, Financial payments to me, Current/Ongoing; Siemens, Research Grant Overall Principal Investigator, Payment to my institution for the grant., Current/Ongoing; Siemens, Other Financial or Material Support, Unpaid consultant, Current/Ongoing; Sora Neuroscience, Other Financial or Material Support, Unpaid consultant, Current/Ongoing; Avid Radiopharmaceuticals, Other Financial or Material Support, Technology transfer to my institution, Current/Ongoing; Cerveau, Other Financial or Material Support, Technology transfer to my institution, Current/Ongoing; Eli Lilly, Scientific/Medical Advisory Board Member, Payment to me, Current/Ongoing
- Bunch, Paul: General Electric (through AUR GERRAF Fellowship), Research Grant Overall Principal Investigator
- Chang, Peter: Avicenna.ai, Stock ownership
- Franceschi, Ana: Biogen, Scientific/Medical Advisory Board Member, Consultant; LMI, Consultant, Other Financial or Material Support; Genentech, Scientific/Medical Advisory Board Member
- Jennings, Jack: Bard/BD, Consultant; Varian, Consultant; Boston Scientific, Consultant; Stryker, Consultant; Merit Medical, Consultant; Agnovos, Consultant
- Johnson, Michele: IschemaView inc, Scientific/Medical Advisory Board Member
- Lee, Seon-Kyu: Alcyone Inc., Consultant; Cernovous, Consultant
- Tanabe, Jody: Icometrix, Scientific/Medical Advisory Board Member; CenExel Rocky Mountain Clinical Research, LLC, Research Grant Site Principal Investigator
- Yedavalli, Vivek: RAPID IschemaView, Consultant
All other individuals in a position to control content have no disclosures.
